Topotecan

Generic Name: Topotecan

Brand Names: Hycamtin, Potactasol, Topotecan Hospira

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₃N_₃O_₅

CAS Number: 123948-87-8

Unique Ingredient Identifier: 7M7YKX2N15

Background: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.

Indication: 用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。

Associated Conditions: Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)

Clinical Trials

Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium

Phase 2

Conditions: Ovarian Clear Cell Carcinoma
Endometrial Clear Cell Carcinoma

Interventions: Drug: Nintedanib
Drug: Paclitaxel
Drug: Pegylated Liposomal Doxorubicin (PLD)
Drug: Topotecan
Drug: Carboplatin
Drug: Doxorubicin

First Posted Date: 2016-08-15

Last Posted Date: 2016-08-15

Lead Sponsor: NHS Greater Glasgow and Clyde

Target Recruit Count: 120

Registration Number: NCT02866370

Locations: 🇬🇧
University College London Hospital, London, United Kingdom
🇬🇧
Great Western Hospital, Swindon, United Kingdom
🇬🇧
The Christie Hospital, Manchester, United Kingdom

and more 14 locations

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

First Posted Date: 2016-06-24

Last Posted Date: 2025-01-10

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 455

Registration Number: NCT02813135

Locations: 🇫🇷
CHU Angers, Angers, France
🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷
CHU Pellegrin, Bordeaux, France

and more 18 locations

High-Risk Neuroblastoma Chemotherapy Without G-CSF

Not Applicable

Completed

Conditions: Neuroblastoma

Interventions: Drug: Topotecan
Drug: Cyclophosphamide
Drug: Cisplatin
Drug: Etoposide
Drug: Vincristine
Drug: Doxorubicin
Drug: Sargramostim

First Posted Date: 2016-06-01

Last Posted Date: 2020-03-12

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 13

Registration Number: NCT02786719

Locations: 🇺🇸
Rady Children's Hospital, San Diego, California, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013

Phase 3

Conditions: Small Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Topotecan
Drug: Etoposide
Device: CT scans

First Posted Date: 2016-04-14

Last Posted Date: 2016-04-25

Lead Sponsor: University Hospital, Angers

Target Recruit Count: 164

Registration Number: NCT02738346

Locations: 🇫🇷
Angers University Hospital, Angers, France

Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors

Phase 2

Terminated

Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor
Recurrent Childhood Ependymoma
Recurrent Childhood Medulloblastoma
Embryonal Tumor With Abundant Neuropil and True Rosettes
Metastatic Malignant Neoplasm to the Leptomeninges

Interventions: Drug: Intra thecal methotrexate
Drug: topotecan
Drug: cyclophosphamide

First Posted Date: 2016-02-17

Last Posted Date: 2020-01-10

Lead Sponsor: Nicklaus Children's Hospital f/k/a Miami Children's Hospital

Target Recruit Count: 3

Registration Number: NCT02684071

Locations: 🇺🇸
Nicklaus Children's Hospital, Miami, Florida, United States

LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies

Phase 1

Terminated

Conditions: Small Cell Lung Cancer
Ovarian Cancer

Interventions: Drug: LCL161
Drug: Topotecan
Drug: Pegylated GCSF (PEG-GCSF)

First Posted Date: 2016-01-07

Last Posted Date: 2023-12-05

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 34

Registration Number: NCT02649673

Locations: 🇺🇸
Florida Cancer Specialists-Sarasota, Sarasota, Florida, United States
🇺🇸
Oklahoma University Health Science Center/Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸
Tennessee Oncology PLLC, Nashville, Tennessee, United States

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

Phase 3

Completed

Conditions: Epithelial Ovarian Cancer
Primary Peritoneal Carcinoma
Fallopian Tube Cancer
Ovarian Cancer

Interventions: Drug: Paclitaxel
Drug: Mirvetuximab soravtansine
Drug: Pegylated liposomal doxorubicin
Drug: Topotecan

First Posted Date: 2015-12-16

Last Posted Date: 2020-10-14

Lead Sponsor: ImmunoGen, Inc.

Target Recruit Count: 366

Registration Number: NCT02631876

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇺🇸
Georgia Regents University (GRU)-Medical College of Georgia (MCG) - Cancer Center, Augusta, Georgia, United States
🇺🇸
UCLA Women's Health Clinical Research Unit - OBGYN, Los Angeles, California, United States

and more 128 locations

Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

Phase 3

Active, not recruiting

Conditions: Fallopian Tube Carcinoma
Cervical Carcinoma
Endometrial Carcinoma
Ovarian Carcinoma
Primary Peritoneal Carcinoma

Interventions: Drug: AL3818
Drug: Carboplatin
Drug: Paclitaxel
Drug: Pegylated Liposomal Doxorubicin (PLD)
Drug: Topotecan

First Posted Date: 2015-10-22

Last Posted Date: 2023-11-08

Lead Sponsor: Advenchen Laboratories, LLC

Target Recruit Count: 294

Registration Number: NCT02584478

Locations: 🇨🇳
The First Hospital of China Medical University, Shenyang, Shenyang, China
🇨🇳
Obstetrics&Gynecology Hospital of Fudan University, Shanghai, Yangpu District, China
🇨🇳
Chongqing University Cancer Hospital, Chongqing, China

and more 38 locations

Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2

Terminated

Conditions: Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma
Malignant Ovarian Endometrioid Tumor
Malignant Ovarian Serous Tumor
Recurrent Fallopian Tube Carcinoma

Interventions: Drug: Topotecan Hydrochloride
Drug: Acetylcysteine

First Posted Date: 2015-10-07

Last Posted Date: 2025-05-04

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 1

Registration Number: NCT02569957

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer

Phase 3

Completed

Conditions: Small-cell Lung Cancer

Interventions: Drug: Doxorubicin (DOX)
Drug: Lurbinectedin (PM01183)
Drug: Topotecan
Drug: Cyclophosphamide (CTX)
Drug: Vincristine (VCR)

First Posted Date: 2015-10-02

Last Posted Date: 2021-10-28

Lead Sponsor: PharmaMar

Target Recruit Count: 613

Registration Number: NCT02566993

Locations: 🇩🇪
Center for Pneumology and Thoracic Surgery, Gerlingen, Germany
🇧🇬
University Multiprofile Hospital for Active Treatment "Sv. Ivan Rilski", Sofia, Sofia, Bulgaria
🇩🇪
Vivantes Klinikum am Urban, Hämatologie und Onkologie, Berlin, Germany

and more 157 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy